Metastatic bone lesions of men in combination with an increase in serum PSA from the point of view of diagnosing carcinomas of unknown primary localization
DOI:
https://doi.org/10.14739/2310-1237.2019.1.166308Keywords:
cancer, prostatic neoplasms, metastases, prostate-specific antigenAbstract
In cases of “malignant neoplasm of unknown origin” of men with bone metastases, it is the serum PSA level that can be crucial for further treatment. The literature describes carcinomas with bone metastases and an increase in the prostate-specific antigen, which were twice refuted by a prostate biopsy but had a positive dynamic during anti-androgen therapy (bicalutamide) in combination with chemotherapy (zoledronic acid).
The aim of the work is to improve diagnostic algorithms, to investigate a complex of morphological, morphometric and immunohistochemical characteristics of metastatic foci in the bones, which are represented by adenocarcinomas of unknown primary localization in men with increased serological marker PSA, compared with primary carcinomas of the prostate gland.
Materials and methods. A retrospective analysis of clinical data, histological and immunohistochemical characteristics of 21 observations of biopsy material from patients with primary carcinoma of the prostate gland (group 1, men aged 56 to 82 years, average 66.00 ± 7.76; median 65) and 10 patients with bone carcinoma metastases without primary localization and increased serum marker PSA (group 2, men aged 43 to 57 years, mean 50.00 ± 9.89; median 46.5) on the basis of the morphological department of diagnostic center “Pharmacy of Medical Academy” for the period 2015–2017.
Results. Morphological, morphometric and immunohistochemical changes of carcinomas of unknown primary site in men with metastatic bone lesions and increased serum marker PSA associated with the acquisition of more aggressive properties were identified in comparison with the primary carcinomas of the prostate gland, which tend to local distribution. There were prevalence of poorly differentiated histological forms of metastatic adenocarcinomas, an objective reduction in the area and perimeter of nuclei (P = 0.00002, P < 0.0001, respectively), possible loss of immunohistochemical markers AMACR (p504s) and AR (androgen receptors) specific for acinar prostate carcinomas (P = 0.008).
Conclusion. The use of minimal primary immunohistochemical panel from cytokeratin, Pan AE1/AE3 (+) / Vimentin(-) / CD45(-) / S100(-) and secondary – cytokeratin 8(+) / PSA(+) / AMACR (p504s)(+) panels / AR(+/-) will allow to prove the conformity of the carcinoma phenotype with unknown primary site in men with metastatic bone lesions and an increase in the PSA serological marker to the form of disseminated prostate carcinoma with justification for the use of appropriate therapy in cases of non-informative prostate biopsy.
References
Iwamura, H., Hatakeyama, S., Tanaka, Y., Tanaka, T., Tokui, N., Yamamoto, H., et al. (2014) A case of metastatic cancer with markedly elevated PSA level that was not detected by repeat prostate biopsy. BMC Res Notes, 7, 64. doi: 10.1186/1756-0500-7-64
Piccioli, A., Maccauro, G., Spinelli, M. S., Biagini, R., & Rossi, B. (2015) Bone metastases of unknown origin: epidemiology and principles of management. J Orthopaed Traumatol, 16(2), 81–86. doi: 10.1007/s10195-015-0344-0
Szwed, E. A., Sliesoraitis, S., Nguyen, Th-C., Nguyen, M-N., Moreb, J. S., Zlotecki, R. A., et al. (2015) New Primary Malignancy Masquerading as Metastatic Prostate Adenocarcinoma. Oncological Medicine, 2015, 358572. doi: 10.1155/2015/358572
Ye, L., Kynaston, H. G., & Jiang, W. G. (2007) Bone metastasis in prostate cancer: Molecular and cellular mechanisms (Review). International journal of molecular medicine, 20(1), 103–111. doi: 10.3892/ijmm.20.1.103
Moul, J. W. (2015) Hormone naïve prostate cancer: predicting and maximizing response intervals. Asian Journal of Andrology, 17(6), 929–35. doi: 10.4103/1008-682X.152821
Ganeshan, Dh., Aparicio, A. M., Morani, A., & Kundra, V. (2017) Pattern and distribution of distant metastases in anaplastic prostate carcinoma: a single-institute experience with 101 patients. AJR Am J Roentgenol, 209(2), 327–332. doi: 10.2214/AJR.16.17214
Alhanafy, A. M., Zanaty, F., Ibrahem, R., & Omar, S. (2018) Prognostic factors for hormone sensitive metastatic prostate cancer: impact of disease volume. Asian Pac J Cancer Prev., 19(4), 1113–1118. doi: 10.22034/APJCP.2018.19.4.1113
Body, J-J., Casimiro, S., & Costa, L. (2015) Targeting bone metastases in prostate cancer: improving clinical outcome. Nat. Rev. Urol. 12(6), 340–356. doi: 10.1038/nrurol.2015.90
Li, D., Lv, H., Hao, X., Hu, B., & Song, Y. (2018) Prognostic value of serum alkaline phosphatase in the survival of prostate cancer: evidence from a meta-analysis. Cancer Management and Research, 10, 3125–3139. doi: 10.2147/CMAR.S174237
Poslavskaya, O. V. (2016) Vyznachennia liniinykh rozmiriv ta ploshch okremykh morfolohichnykh ob’iektiv na mikrofotohrafiiakh za dopomohoiu prohramy ImageJ [Determination of linear dimensions and square surfaces areas of morphological objects on micrographs using ImageJ software]. Morphologia. 10(3), 377-81. [in Ukrainian].
Poslavska, O. V., Shponka, I. S., Hritsenko, P. A., & Alekseenko, O. A. (2016) Morfometrychnyi analiz pantsytokeratyn-nehatyvnykh neplastychnykh ushkodzhen limfatychnykh vuzliv shyi [Morphometric analysis of “pancitokeratin-positive” neoplastic lesions of the lymph nodes of the neck]. Medychni perspektyvy, 23(1), 30–37. [in Ukrainian]. doi: 10.14739/2310-1237.2017.3.118730
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
